This is a preview of subscription content, log in via an institution to check access.
Notes
Funded by Novartis Pharmaceuticals UK Ltd.
Reference
Claxton L, et al. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. PharmacoEconomics : 27 Oct 2016. Available from: URL: http://dx.doi.org/10.1007/s40273-016-0459-z
Rights and permissions
About this article
Cite this article
Simulation models "feasible" alternatives in wAMD studies. PharmacoEcon Outcomes News 766, 30 (2016). https://doi.org/10.1007/s40274-016-3551-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3551-x